Using the Biology of Chronic Lymphocytic Leukemia to Choose Treatment

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

(2011) X. C. Badoux et al.   BLOOD

A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

(2011) Peter Hillmen et al.   BRITISH JOURNAL OF HAEMATOLOGY

An overview of chronic lymphocytic leukaemia biology

(2010) M.T.S. Bertilaccio et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Telomere disrupts, CLL progresses

(2010) M. Ladetto   BLOOD

Phosphatidylinositol 3-kinase-  inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

(2010) S. E. M. Herman et al.   BLOOD

TP53Mutation and Survival in Chronic Lymphocytic Leukemia

(2010) Thorsten Zenz et al.   JOURNAL OF CLINICAL ONCOLOGY

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

(2010) M Hallek et al.   LANCET

TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations

(2010) T Zenz et al.   LEUKEMIA

The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia

(2010) Graham Packham et al.   SEMINARS IN CANCER BIOLOGY

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

(2009) T. Zenz et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia

(2009) Apostolia-Maria Tsimberidou et al.   CANCER

Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

(2009) Francesc Bosch et al.   JOURNAL OF CLINICAL ONCOLOGY

Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens

(2008) K. I. Lin et al.   BLOOD

Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission - long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)

(2008) Carmen D. Schweighofer et al.   BRITISH JOURNAL OF HAEMATOLOGY

New Insights into the Early Molecular Events Underlying B Cell Activation

(2008) Naomi E. Harwood et al.   IMMUNITY